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Background: Accumulating evidence has shown that up-regulation of microRNA-25(miR-25) is associated with the
prognosis of several types of human malignant solid tumors. However, whether miR-25 expression has influence on
the prognosis of hepatocellular carcinoma (HCC) is still unknown.
Methods: The differentially expressed amount of the miR-25 was validated in triplicate by quantitative
reverse-transcription polymerase chain reaction (qRT-PCR). Survival rate was analyzed by log-rank test, and
survival curves were plotted according to Kaplan–Meier. Multivariate analysis of the prognostic factors was
performed with Cox regression model.
Results: The expression of miR-25 was significantly upregulated in HCC tissues when compared with adjacent
normal tissues (p<0.0001). Patients who had high miR-25 expression had a shorter overall survival than patients
who had low miR-25 expression (median overall survival, 31.0 months versus 42.9 months, p=0.0192). The
multivariate Cox regression analysis indicated that miR-25 expression (HR=2.179; p=0.001), TNM stage (HR=1.782;
p=0.014), and vein invasion (HR=1.624; p=0.020) were independent prognostic factors for overall survival.
Conclusion: Our data suggests that the overexpression of miR-25 in HCC tissues is of predictive value on poor
prognosis.
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eu/vs/1989618421114309Introduction
Hepatocellular carcinoma (HCC) is one of the most malig-
nant solid tumors and is the second leading cause of
cancer-related mortality [1]. The established risk factors of
HCC are viral hepatitis, alcohol abuse, and non-alcoholic
fatty liver disease [2]. HCC is often diagnosed at an ad-
vanced stage, and it is not amenable to standard chemo-
therapy and is resistant to radiotherapy. In most cases,
surgical resection and liver transplantation remain the only
curative treatment options. Frequent tumor metastasis and
recurrence after surgical intervention lead to the dismal
outcome of patients with HCC. The 5-year survival rate of
patients with HCC is approximately 5%, and over 650,000
people die of HCC each year worldwide [3]. The prediction
of the prognosis and accurate patient stratification are* Correspondence: dr_suzhongxue@126.com
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unless otherwise stated.crucial to optimize personalised treatment. This is currently
performed by several staging scores, including the Barce-
lona Clinic Liver Cancer (BCLC) stage and the Cancer of
the Liver Italian Program (CLIP) score [4,5]. Modifications
of these staging systems by the addition of new biomarkers,
in particular those better reflecting tumor aggressiveness,
are likely to improve the prognostic assessment of HCC pa-
tients and could therefore fulfill a clinical need. Researchers
have found some new prognostic markers of HCC, such as
squamous cellular carcinoma antigen, SOX9, and L1 cell
adhesion molecule [6-9].
The microRNAs (miRNAs) are a class of highly con-
served short noncoding RNAs, which suppress protein
expression by inhibiting translation or inducing mRNA
degradation by binding to the 3′UTR of target mRNAs
[10,11]. Beyond the involvement in diverse biological
processes, it has been well demonstrated that deregula-
tion or dysfunction of miRNAs can contribute to cancer
development [12,13].This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Relationship between miR-25 expression level and
clinicopathologic parameters of hepatocellular carcinoma
Factor No. miR-25 expression P value
Gender
Male 81 8.34 ± 4.85
Female 50 8.11 ± 4.63 0.62
Age at diagnosis(year)
≤50 53 8.01 ± 5.11
>50 78 8.49 ± 3.89 0.21
Tumor size(cm)
≤5 62 7.99 ± 5.13
>5 69 9.01 ± 3.79 0.13
Tumor number
Solitary 70 8.13 ± 4.34
Multiple 61 8.57 ± 4.89 0.51
TNM stage
I-II 72 6.34 ± 3.12
III-IV 59 11.01 ± 5.61 0.01
Vein invasion
Presence 79 9.12 ± 4.89
Absence 52 7.31 ± 4.19 0.24
Cirrhosis
Negative 44 7.12 ± 3.19
Positive 87 8.89 ± 5.38 0.17
Hepatitis B virus infection
Negative 42 6.17 ± 4.65
Positive 89 9.21 ± 4.13 0.09
Serum AFP level (ng/ml)
≤25 54 6.02 ± 3.87
>25 77 10.99 ± 5.44 0.02
AFP,α-fetoprotein.
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includes miR-106b, miR-93 and miR-25, that is located
within intron 13 of the minichromosome maintenance
protein 7(MCM7) gene on chromosome 7q22.1 [14,15].
Accumulating evidence has shown that up-regulation of
miR-25 is associated with the prognosis of several human
malignant solid tumors, including those of the stomach,
ovary and prostate [16-18].
Recently, Li Y et al. found that the miR-106b~25 cluster
was overexpressed in HCC tissues as well as cell lines,
suggesting an important role of miR-106b~25 cluster in
carcinogenesis and development of HCC [19]. However,
the clinical relevance of miR-25 has not been studied yet,
and whether miR-25 expression has influence on the prog-
nosis of HCC is still unknown. Therefore, in the present
study, we investigated the feasibility of miR-25 as a novel
prognostic biomarker for HCC.
Materials and methods
Patients and Tissue Specimens
A total of 131 fresh specimens of HCC and paracarcino-
matous liver tissues were obtained from 131 patients who
underwent hepatic resection at Provincial Hospital affili-
ated to ShanDong University between June 2006 and July
2012. Among all the subjects, the mean follow-up period
was 47 months (from 11 months to 65 months), and there
was no censored case. All these tissues were immediately
stored in liquid nitrogen and kept freshly frozen at − 80°C.
Written informed consent was accomplished from the
patients for publication of this study and any accom-
panying images. Study protocol was approved by the
Ethics Committee of Provincial Hospital affiliated to
ShanDong University. Before surgical therapy, none of
the patients had received neoadjuvant chemotherapy,
radiation therapy, or immunotherapy. Related import-
ant clinical information, including age, gender, serum
level of α-fetoprotein (AFP), liver cirrhosis, Hepatitis B
virus infection, tumor diameter, number of tumor nod-
ules, and TNM stage were collected from each patient’s
medical records. Clinical staging was performed accord-
ing to the 2002 American Joint Committee on Cancer/
International Union Against Cancer TNM staging sys-
tem [20]. Patient characteristics were shown in Table 1.
RNA isolation and quantitative RT-PCR of miRNA-25
Total RNA was isolated from frozen specimen by hom-
ogenizing tissue in Trizol reagent (Invitrogen, Carlsbad,
CA, USA), according to the manufacturer’s instructions.
The purity and concentration of RNA were determined
using NanoDrop 1000 spectrophotometer (Thermo
Scientific, Wilmington, DE, USA). The differentially
expressed amount of the miR-25 was validated in tripli-
cate by quantitative reverse-transcription polymerase
chain reaction (qRT-PCR). Briefly, 2 ug of RNA wasadded to RT reaction, and then, the cDNA served as the
template for amplification of PCR with sequence-specific
primers (Sangon Biotech, Shanghai, China) using SYBR
PrimeScript miRNA RT-PCR kit (Takara Biotechnology Co.
Ltd, Dalian, China) on the 7500 Real-Time PCR systems
(Applied Biosystems, Carlsbad, CA, USA). The PCR cycling
profile was denatured at 95°C for 30 s, followed by 40 cycles
of annealing at 95°C for 5 s, and extension at 60°C for 34 s.
Small nucleolar RNA U6 was used as an internal standard
for normalization. The cycle threshold (CT) value was cal-
culated. The 2-ΔCT (ΔCT=CTmiR25-CTU6 RNA) method was
used to quantify relative amount of miR-25.
Statistical analysis
Statistical analyses were performed using SPSS 13.0 soft-
ware (Chicago, Ill., USA) and GraphPad Prism 5 (GraphPad
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level of miR-25 between HCC tissues and adjacent normal
tissues was performed using the two-sample Student’s t test.
The correlation between the expression level of miR-25
and clinicopathological characters was assessed with the
two-sample Student’s t test. Survival rate was analyzed by
log-rank test, and survival curves were plotted according to
Kaplan–Meier. Multivariate analysis of the prognostic fac-
tors was performed with Cox regression model. All tests
were two tailed and results with P<0.05 were considered
statistically significant.
Results
The expression level of miR-25 in HCC samples and its
relationship with clinicopathological characteristics
The expression of miR-25 was significantly upregulated in
HCC tissues (mean relative expression level: 8.287,
SD=4.711) when compared with adjacent normal tissues
(mean relative expression level: 4.177, SD=2.386, P<0.0001,
Figure 1). The relationship between miR-25 expression level
with clinicopathological variables of HCC patients was
shown in Table 1. The relative miR-25 expression levels
were significantly positively correlated with serum AFP
(p=0.02) and TNM stage (p=0.01).
However, there was no significantly correlation of miR-
25 expression with other clinical features such as gender
(p=0.62), age (p=0.21), liver cirrhosis (p=0.17), Hepatitis B
virus infection (p=0.09), vein invasion (p=0.24), tumor diam-
eter (p=0.13), or number of tumor nodules (p=0.51).
The expression levels of miR-25 correlate with prognosis
of patients with HCC
Considering that the level of miR-25 expression was sig-
nificantly correlated with TNM stage and serum AFPFigure 1 Comparison of miR-25 expression levels between
hepatocellular carcinoma tissues and adjacent normal tissues.
Analysis using the two sample Student’ s t test showed that the
relative expression levels of miR-25 in the hepatocellular carcinoma
tissues were significantly higher than those in adjacent normal
tissues (p<0.0001) SE, Standard Error.level, we hypothesized that miR-25 might affect the prog-
nosis of HCC patients. To confirm this possibility, the
miR-25 expression level and the prognosis of patients with
HCC were analyzed by using the Kaplan–Meier method.
The results indicated that patients who had high miR-25
expression had a shorter overall survival than patients
who had low miR-25 expression (median overall survival,
31 months versus 42.9 months, p=0.0192; Figure 2). The
multivariate Cox regression analysis indicated that miR-25
expression (HR=2.179; p=0.001), TNM stage (HR=1.782;
p=0.014), and vein invasion (HR=1.624; p=0.020) were in-
dependent prognostic factors for overall survival (shown
in Table 2).
Discussion
Although a growing number of novel treatment strategies
have been developed for HCC, such as molecular targeted
therapy and gene therapy, to our disappointment, satisfac-
tory therapeutic outcomes have not been achieved [21,22].
Considering that the survival rate of HCC is still low, fur-
ther identification of new prognostic markers remains im-
portant for the prevention and treatment of HCC.
The discovery that noncoding components of the gen-
ome, including microRNA, can contribute to the pathogen-
esis of cancer has led investigators to contemplate using
these molecules to guide clinical decision making [23]. So
far, there are more than 1000 microRNAs annotated by the
latest version of miRBase. The expression of miRNAs is re-
markably deregulated in HCC, strongly suggesting that
miRNAs are involved in the initiation and progression of
this disease. MiR-25 is a member of the miR-106b~25 clus-
ter, which includes miR-106b, miR-93 and miR-25, that is
located within intron 13 of the minichromosome mainten-
ance protein 7 (MCM7) gene on chromosome 7q22.1 [14].Figure 2 Survival analysis of 131 hepatocellular carcinoma
patients by Kaplan-Meier method. Overall survival rate in patients
with high miR-25 expression was significantly lower than that in
patients with low miR-25 expression (p=0.0192).
Table 2 multivariate analyses of prognostic factors in
hepatocellular carcinoma
Variable Subset Overall survival
HR 95% CI P
miR-25 expression High/low 2.179 1.876-4.335 0.001
Gender Male/female 0.982 0.901-1.003 0.652
Age at diagnosis >50/≤50 1.231 0.922-1.523 0.212
Tumor size >5/≤5 1.479 0.991-2.127 0.090
Tumor number Multiple/solitary 1.854 0.823-2.132 0.121
TNM stage III-IV/I-II 1.782 1.389-2.993 0.014
Vein invasion Presence/absence 1.624 1.233-1.981 0.020
Cirrhosis Positive/negative 1.027 0.876-1.535 0.320
Hepatitis B virus infection Positive/negative 1.002 0.892-1.337 0.417
Serum AFP level >25/≤25 1.377 0.882-1.335 0.398
CI, confidence interval; HR, hazard ratio; miR-25, microRNA-25.
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was up-regulated significantly in human stomach cancer,
ovarian cancer, and prostate cancer [16-18]. In the study by
Kim BH et al., miR-25 was found to be up-regulated in hu-
man gastric carcinoma tissues when compared to adjacent
non-neoplastic tissues. The high expression of miR-25 in
gastric carcinoma tissues may be a high risk factor associ-
ated with tumor penetration through serosa, lymph node
metastasis, distant metastasis, and poor long-term survival
in patients undergoing radical resection and adjuvant sys-
temic chemotherapy [16]. Poliseno L et al. found that miR-
106b~25 cluster was aberrantly overexpressed in human
prostate cancer, which potentiated cellular transformation
both in vitro and in vivo. They demonstrated that the in-
tronic miR-106b~25cluster cooperated with its host gene
MCM7 in cellular transformation both in vitro and in vivo
[17]. Zhang H et al. have found that miR-25 was strongly
up-regulated in ovarian cancer tissue versus adjacent non-
tumor tissue. The expression levels of miR-25 in ovarian
cancer cell lines were similar with ovarian cancer samples
compared with the normal ovarian epithelial cells. Overex-
pression of miR-25 in ovarian cancer cells enhanced cell
proliferation whereas down-regulation of miR-25 induced
apoptosis. The effects of miR-25 abrogation were partly
mediated by the intrinsic apoptosis pathway. Many pro-
apoptotic proteins such as Bim, Bax and caspase-3 were
up-regulated after transfection [18]. However, investigators
also found that expression of miR-25 was down-regulated
in other cancer. Li Q et al. found that the expression of
miR-25 was down-regulated in colon cancer, and miR-25
might suppress the proliferation and migration of colon
cancer cells as a tumor suppressor gene in vitro and in vivo
[24]. Therefore, we speculate that the function of miR-25 is
tissue specific.
Li Y et al. have found that miR-25 was strongly up-
regulated in HCC tissue when compared with thecorresponding paired non-tumor samples. However, the
clinical significance of miR-25 gene expression in HCC re-
mains unclear. In the present study, we found that miR-25
expression was proven to be associated with advanced
TNM stage, suggesting that miR-25 might be involved in
the carcinogenesis and metastasis of HCC. More import-
antly, we proved that patients with a high expression of
miR-25 tended to have shorter survival than patients with
lower levels, indicating that high miR-25 level is a marker
of poor prognosis for patients with HCC. However, the
precise molecular mechanisms behind the altered expres-
sion of miR-25 in HCC and its function are not very clear.
In the study by Li Y et al., knock-down studies for the
miR-106b-25cluster, which includes miR-106b, miR-93
and miR-25, showed that the expression of the cluster was
necessary for cell proliferation and for anchorage inde-
pendent growth [19]. Additional studies are needed to
more clearly and comprehensively articulate the molecular
mechanisms of both the cause and the effects of altered
expression of miR-25 in the development and/or progres-
sion of HCC.
In summary, to the best of our knowledge, the present
study is the first to report the differential expression of
miR-25 in HCC and the possible use of miR-25 as a novel
prognostic marker in HCC. The present findings demon-
strate high expression of miR-25 in HCC tissue, which is
associated with a poor prognosis in HCC patients. Further
studies are needed to elucidate the mechanisms of action
of miR-25 in HCC.
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